News
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
A Novo Nordisk spokesperson said: "Treatment decisions should be made together with a healthcare provider who can evaluate the appropriateness of using a GLP-1 based on assessment of a patient’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback